UPDATED: Senseonics nabs $10M in venture funding for its implantable blood glucose monitor

Senseonics, the maker of an implantable continuous glucose monitor device, has picked up $10 million in venture funding, according to a regulatory filing.

The company, based in Germantown, MD, didn't disclose its intentions for the funds in the SEC filing, though when it raised $20 million in venture capital in 2014, Senseonics said the money was earmarked for obtaining a CE mark and to start investigational device exemption trials in the U.S.

The Senseonics system includes a tiny sensor, external transmitters and a smartphone application. The sensor is implanted in the skin of the upper arm, and is designed to work for 6 months or longer before replacement.

To date, Senseonics has raised a total of at least $94 million and has investors that include Anthem Capital, Delphi Ventures and Healthcare Ventures.

In May, the company said it was teaming with Sweden-based Rubin Medical, an insulin pump distributor, for the distribution of its system in Sweden, Norway and Denmark. The company has said it expects to get a CE mark for its CGM device by the end of this year.

Senseonics isn't alone in the CGM market. Earlier this week, Dexcom ($DXCM) announced it is working with Google ($GOOG) to develop cheaper, miniaturized glucose monitors that would combine the search engine giant's electronics platform with Dexcom's technology.

- see the SEC filing

UPDATES to correct $10 million raised in latest round of funding

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.